Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "immunohistochemistry"

12 News Found

Enhertu Phase III results to redefine how metastatic breast cancer is classifed
Biotech | February 21, 2022

Enhertu Phase III results to redefine how metastatic breast cancer is classifed

Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.

AMPATH launches its pathology laboratory in Mumbai
Clinical Trials | November 29, 2021

AMPATH launches its pathology laboratory in Mumbai

The company has has 10 existing labs in India

Latest Stories

Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy

Leinco Technologies and CellCarta partner to advance proteomics in immuno-oncology

Sanofi Consumer Healthcare reports 33% revenue growth in Q1 FY26; PAT rises 36%

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Dr Maloy Ghosh Chief Scientific Officer, Zumutor Biologics
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
Venkat Nelabhotla Co-Founder, President & CEO, Vyome Holdings, Inc.
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Ganesh Bade Head Bioprocessing, India, Avantor

Packaging